论文部分内容阅读
目的：探讨巴曲抗栓酶治疗急性脑栓塞的疗效。方法：经ＣＴ诊断的急性脑栓塞病人４８例，随机分为巴曲抗栓酶组（治疗组）和右旋糖酐组（对照组）各２４例。治疗组按巴曲抗栓酶剂量分为１０ＢＵ，ｉｖ，ｄｒｉｐ，ｑｄ×３ｄ和５ＢＵ，ｉｖｄｒｉｐ，ｑｄ×７ｄ２个亚组，按开始用药时间分为２４ｈ内和７２ｈ内２个亚组。对照组用右旋糖酐－４０葡萄糖液５００ｍＬ／ｄ，ｉｖｄｒｉｐ×１０ｄ。结果：治疗组在治疗１ｗｋ末、１ｍｏ末神经功能缺损评分的平均减少分数（ＭＤＳ）比对照组增加，但仅在１ｗｋ末时有显著性差异；剂量不同在疗效上无显著差异，而开始治疗时间２４ｈ内优于７２ｈ内治疗组。未见不良反应。结论：巴曲抗栓酶治疗急性脑栓塞疗效较好，但宜早期使用，疗程可延长。
Objective: To investigate the efficacy of batroxobin in the treatment of acute cerebral embolism. Methods: Forty-eight patients with acute cerebral embolism diagnosed by CT were randomly divided into two groups, each of which was treated with batroxobin (treatment group) and dextran group (control group). The treatment group was divided into two subgroups: 10BU, iv, drip, qd × 3d and 5BU, ivdrip, qd × 7d2 according to the dose of batroxobin. The control group dextran 40 glucose solution 500mL / d, ivdrip × 10d. Results: In the treatment group, the mean decrease score (MDS) of neurological deficit score at the end of 1wk and 1mo end was higher than that of the control group, but only at the end of 1wk. There was no significant difference between the two groups Within 24h time better than 72h treatment group. No adverse reactions. Conclusion: Batroxobin is effective in the treatment of acute cerebral embolism, but should be used early, the course of treatment can be extended.